Toronto, Ontario – February 1, 2013 -- Theralase Technologies Inc.
(TSX-V: TLT) announced that effective today Mr. Matthew Perraton PFP, FMA, FCSI
and Mr. Guy J. Anderson BA,
CFP, CIM, FMA, FCSI, MBA have agreed to serve on the company's Board of
Directors.
Mr. Perraton and Mr. Anderson join Mr. Donald Moore, Mr. Randy Bruder
and Mr. Roger Dumoulin-White on the board and will be instrumental in helping
Theralase secure the financing required to fuel Theralase’s growth over the
next 5 to 10 years.
Mr. Perraton brings over 13 years of financial experience to
Theralase, most recently as a Financial Planner for TD Waterhouse. Prior to his
current position, Mr. Perraton held progressively higher positions with BMO
Nesbitt Burns and Bank of Nova Scotia.
Mr. Perraton stated that, “I am delighted to join the board at
Theralase, as I am absolutely convinced that Theralase is on the right path for
shareholder value with both their therapeutic laser technology for healing
tissue and their Photo Dynamic Compound (PDC) technology for destroying cancer.
Their technology is far superior to anything I have seen on the market and
properly financed I see great opportunities for Theralase in the near term”.
Mr. Anderson brings over 16 years of financial experience to
Theralase, most recently as a Wealth Management and Personal Finance Advisor
with the Investment Planning Counsel. Prior to his current position, Mr.
Anderson held progressively higher positions with Franklin Templeton Investments
Canada, T.E. Financial and Bank of Nova Scotia.
Mr. Anderson stated that, “I have followed the progress of Theralase
over the last 4 to 5 years and have been amazed that the company has been able
to advance such cutting-edge technology on a shoe string budget. I join Matt in
saying that properly capitalized there is nothing that stands in the way of
Theralase’s success. Their technology is not only the best on the market, but their
management team has demonstrated an ability to survive in choppy markets and to
advance the technology to the point that it is ready to grow in leaps and
bounds”.
Roger Dumoulin-White, President and CEO, Theralase Technologies Inc. stated,
“I am pleased that Matt and Guy have agreed to serve on our Board of Directors.
They both have broad experience in financial management, regulatory compliance
and strategic planning and both possess the vision and financial acumen to
drive Theralase forward to achieve our full potential. I welcome Matt and Guy
to the board and am confident that both will serve the company and the
shareholders well during their tenure.”
Mr. Dumoulin-White also stated, “We are all saddened by the loss of
our long time board member Mr. John “Jack” Murphy late last year and we would like to take this opportunity to
express our profound condolences to Jack’s family. He was a strong member of
our team, an insightful director and always a pleasure to work with. His
business judgment and knowledge will be sorely missed”.
About
Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops,
manufactures and markets patented, superpulsed laser technology utilized in
biostimulation and biodestruction applications. Theralase technology is safe
and effective in treating pain, inflammation and for tissue regeneration of
neural muscular skeletal conditions and wound healing. Theralase is currently
developing patented Photo Dynamic Compounds (PDCs) that are able to target and
destroy cancers, bacteria and viruses when light activated by Theralase’s
proprietary and patented laser technology.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information
Roger Dumoulin-White
President & CEO
416-694-7246 ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-694-7246 ext. 224
khachey@theralase.com
Arkady Mandel
Chief Scientific Officer
416-694-7246 ext. 242
amandel@theralase.com
Greg Bewsh
Director of Investor Relations
416-694-7246 ext. 258
gbewsh@theralase.com
